AC
SGMO

Alexandria Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Alexandria Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$8.65M Buy
960,470
+4,943
+0.5% +$48.9K 0.8% 39
2021
Q2 		$11.4M Sell
955,527
-12,978
-1% -$147K 1.06% 21
2021
Q1 		$12.1M Sell
968,505
-35,220
-4% -$475K 1.23% 14
2020
Q4 		$15.7M Sell
1,003,725
-13,105
-1% -$154K 1.66% 8
2020
Q3 		$9.69M Buy
1,016,830
+4,775
+0.5% +$51.6K 1.16% 17
2020
Q2 		$9.07M Buy
1,012,055
+6,936
+0.7% +$64.3K 1.18% 16
2020
Q1 		$6.4M Buy
1,005,119
+48,235
+5% +$358K 1.05% 29
2019
Q4 		$8.01M Buy
956,884
+53,350
+6% +$491K 1.07% 26
2019
Q3 		$8.18M Sell
903,534
-9,469
-1% -$106K 1.21% 22
2019
Q2 		$9.83M Sell
913,003
-3,150
-0.3% -$33.5K 1.4% 16
2019
Q1 		$8.74M Buy
916,153
+22,350
+3% +$228K 1.27% 20
2018
Q4 		$10.3M Sell
893,803
-1,626
-0.2% -$20.2K 1.67% 8
2018
Q3 		$15.2M Sell
895,429
-1,753
-0.2% -$26.6K 2.23% 4
2018
Q2 		$12.7M Buy
897,182
+15,649
+2% +$260K 1.91% 8
2018
Q1 		$16.7M Sell
881,533
-43,994
-5% -$941K 2.49% 4
2017
Q4 		$15.2M Buy
+925,527
New +$13.8M 2.21% 6

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alexandria Capital's SGMO Position: Q3 2021 in Review

Alexandria Capital increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 0.52% in Q3 2021, buying an estimated $48.9K and bringing the position to 960,470 shares worth $8.65M. The position accounts for 0.8% of the portfolio, ranked #39.

Alexandria Capital first reported a position in SGMO in Q4 2017 and has held it in 16 quarters since. The position peaked at $16.7M in Q1 2018. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

  • Alexandria Capital held 960,470 shares of SANGAMO THERAPEUTICS INC worth $8.65M as of Q3 2021.
  • Alexandria Capital bought 4,943 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $48.9K.
  • SANGAMO THERAPEUTICS INC made up 0.8% of Alexandria Capital's portfolio in Q3 2021, its #39 holding.
  • Alexandria Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and has held it in 16 quarters since.
  • Alexandria Capital's SANGAMO THERAPEUTICS INC position peaked at $16.7M in Q1 2018.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.